Institutional shares held 31.1 Million
646K calls
670K puts
Total value of holdings $353M
$7.34M calls
$7.6M puts
Market Cap $292M
25,757,000 Shares Out.
Institutional ownership 120.67%
# of Institutions 177


Latest Institutional Activity in KROS

Top Purchases

Q4 2024
Braidwell LP Shares Held: 1.89M ($21.5M)
Q4 2024
Lynx1 Capital Management LP Shares Held: 544K ($6.17M)
Q4 2024
Nantahala Capital Management, LLC Shares Held: 915K ($10.4M)
Q4 2024
Mangrove Partners Shares Held: 736K ($8.36M)
Q4 2024
Catalio Capital Management, LP Shares Held: 407K ($4.62M)

Top Sells

Q4 2024
Point72 Asset Management, L.P. Shares Held: 1.59K ($18.1K)
Q4 2024
Alkeon Capital Management LLC Shares Held: 1.1M ($12.5M)
Q4 2024
Price T Rowe Associates Inc Shares Held: 910K ($10.3M)
Q4 2024
Adar1 Capital Management, LLC Shares Held: 23.2K ($264K)
Q4 2024
Woodline Partners LP Shares Held: 388K ($4.4M)

About KROS

Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need. The company's lead protein therapeutic product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, and in patients with myelofibrosis. It is also developing small molecule product candidate KER-047 that is being developed for the treatment of anemia, and is currently in Phase 1 clinical trial; and KER-012, which is in Phase 1 clinical trial to treat disorders associated with bone loss, such as osteoporosis and osteogenesis imperfecta, and for the treatment of pulmonary arterial hypertension. The company was incorporated in 2015 and is headquartered in Lexington, Massachusetts.


Insider Transactions at KROS

Insider Transaction List

View all
Date Insider Transaction Ownership Type Shares Traded Value / Price
View All Transactions

Last 12 Months Summary

Buy / Acquisition
148K Shares
From 3 Insiders
Grant, award, or other acquisition 148K shares
Sell / Disposition
500K Shares
From 2 Insiders
Open market or private sale 500K shares

Track Institutional and Insider Activities on KROS

Follow Keros Therapeutics, Inc. and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells KROS shares.

Notify only if

Insider Trading

Get notified when an Keros Therapeutics, Inc. insider buys or sells KROS shares.

Notify only if

News

Receive news related to Keros Therapeutics, Inc.

Track Activities on KROS